Join
Live feed
·
PRReleasevia Quantisnow
Corcept Therapeutics Incorporated logo

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

ByQuantisnow·Wall Street's wire, on your screen.
CORT· Corcept Therapeutics Incorporated
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CORT (Corcept Therapeutics Incorporated) and more on Quantisnow.